Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-10-27
|
maribavir |
cytomegalovirus infections |
2 |
Shire (UK - USA) |
Infectious diseases |
2016-10-27
|
QR-010 |
cystic fibrosis |
1 |
ProQR Therapeutics (The Netherlands) |
Rare diseases - Genetic diseases - Lung diseases |
2016-10-27
|
ALXN1210 (ravulizumab - Fc- and CDR-modified humanised monoclonal antibody against C5) |
paroxysmal nocturnal hemoglobinuria (PNH) |
3 |
Alexion Pharmaceuticals (USA - CT) |
Rare diseases - Immunological diseases |
2016-10-27
|
ALXN1210 (ravulizumab - Fc- and CDR-modified humanised monoclonal antibody against C5) |
atypical hemolytic uremic syndrome (aHUS) |
3 |
Alexion Pharmaceuticals (USA - CT) |
Rare diseases - Kidney diseases - Renal diseases |
2016-10-27
|
THN102 - combination of modafinil and flecainide |
narcolepsy |
2 |
Theranexus (France) |
Rare diseases - Neurological diseases |
2016-10-27
|
relamorelin (RM-131) |
gastroparesis in patients with type 1 and type 2 diabetes |
2b |
Actavis (Ireland) Rhythm, now Motus Therapeutics (USA - IL) |
Gastrointestinal diseases - Metabolic diseases |
2016-10-26
|
venetoclax (RG7601, GDC-0199/ABT-199) and ABBV-838 |
multiple myeloma |
1 |
Abbvie (USA - IL) |
Cancer - Oncology |
2016-10-26
|
F901318 (2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]- phenyl}-2-oxo-acetamide) |
aspergillosis |
preclinical |
F2G (UK) |
Infectious diseases |
2016-10-26
|
Viaskin® Peanut |
peanut allergy |
2 |
Consortium for Food Allergy Research - CoFAR (USA) DBV Technologies (France) |
Allergic diseases - Immunological diseases |
2016-10-26
|
BI 695501 (biosimilar version of Humira® (adalimumab)) |
rheumatoid arthritis |
3 |
Boehringer Ingelheim (Germany) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2016-10-26
|
ATX-GD-459 |
Graves' disease |
1 |
Apitope (UK - Belgium) |
Autoimmune diseases |
2016-10-25
|
apatorsen (OGX-427) |
metastatic bladder cancer |
2 |
OncoGenex Pharmaceuticals (USA - WA) |
Cancer - Oncology |
2016-10-25
|
PRX-102 (alpha-galactosidase-A) |
Fabry disease |
3 |
Protalix BioTherapeutics (Israel) |
Rare diseases - Genetic diseases |
2016-10-24
|
bavituximab and anti PD-L1 therapy |
triple-negative breast cancer (TNBC) |
preclinical |
Peregrine Pharmaceuticals (USA - CA) |
Cancer - Oncology |
2016-10-21
|
pexidartinib (PLX3397) |
tenosynovial giant cell tumour |
3 |
Daiichi Sankyo (Japan) |
Cancer - Oncology |
2016-10-21
|
napabucasin (BBI608) |
colorectal cancer |
3 |
Boston Biomedical (USA - MA) |
Cancer - Oncology |
2016-10-20
|
ALKS 5461 |
major depressive disorder (MDD) |
3 |
Alkermes (Ireland) |
CNS diseases - Mental diseases |
2016-10-20
|
TGR-1202 and carfilzomib |
relapsed and refractory non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) |
1-2 |
TG Therapeutics (USA - NY) |
Cancer - Oncology |
2016-10-20
|
selonsertib (GS-4997) |
pulmonary arterial hypertension (PAH) |
2 |
Gilead Sciences (USA - CA) |
Rare diseases - Cardiovascular diseases |
2016-10-20
|
selonsertib (GS-4997) |
diabetic kidney disease |
2 |
Gilead Sciences (USA - CA) |
Kidney diseases - Metabolic diseases - Renal diseases |